Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India

Kashyap, Ananth; Balaji, M N; Chhabra, Manik; Rashid, Muhammed; Muragundi, PM

doi:10.1080/14737167.2019.1637735

Cited by 13 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the first cost comparison study that addresses all the anticancer drugs available at Jan Aushadhi Kendra compared with the branded drugs marketed in India. Our results substantiate the earlier observations of Kashyap and co-workers [ 13 ]. They have also reported that replacing generic anticancer drugs can result in substantial cost savings and benefit the patient requiring curative chemotherapy for breast cancer.…”

Section: Discussionsupporting

confidence: 93%

“…In pharmacy research, cost-minimization analysis (CMA) is extremely important and is aimed at ascertaining the least costly drug or a combination to reduce the financial toxicity to the patient and society [ 13 ]. Previous studies by Kolasani and co-workers have shown that a substantial difference exists in the cost variance (CV) for different brands (marketed in the same dose and dosage) of the approved anticancer drugs in India [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

“…Previous studies by Kolasani and co-workers have shown that a substantial difference exists in the cost variance (CV) for different brands (marketed in the same dose and dosage) of the approved anticancer drugs in India [ 14 ]. With regard to the drugs available at the Jan Aushadhi stores, reports suggest that when compared to the branded drugs, a substantial variation in the costs exists for psychotropic medicines [ 15 ], anticancer drugs used for treating breast cancer [ 13 ], and for anticoagulants, antiplatelets, and fibrinolytic used for thromboembolic disorders [ 16 ]. For the first time, this study compares the cost of generic anticancer drugs available at Jan Aushadhi pharmacies with the costliest and cheapest branded drugs with the same molecular composition and dose marketed throughout India.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study

George¹,

Baliga²

2021

Cureus

View full text Add to dashboard Cite

Introduction: In India, the costs of cancer drugs are exorbitant and cause significant financial toxicity to the affected patient and their family members. Considering this, Jan Aushadhi pharmacy stores were established across the country by the government of India with the objective of providing cheap generic medicines to patients. The objective of this study was to perform a cost comparison study of generic chemotherapeutic drugs provided through Jan Aushadhi pharmacies versus their branded counterparts. This will help patients and physicians get first-hand information on the cost variation between generic and branded anticancer drugs in India. Materials and Methods: The cost of Jan Aushadhi generic drugs and the cost of the most expensive and cheapest marketed branded drugs for the same molecule and dose were ascertained and presented in both Indian Rupees (INR) and US Dollars (as of July 2021). Finally, the difference in costs in INR, cost ratio, and cost variance were calculated, comparing the price of the Jan Aushadhi generic drugs with the most expensive and the cheapest branded drug in the same category. Results: Compared to branded drugs, all the Jan Ausadhi generic drugs were cheaper, except one (methotrexate). The highest cost difference was observed for docetaxel, while the least was observed for methotrexate tablets (2.5 mg). The highest cost ratio (22.24) and cost variance (3327.56) were observed for doxorubicin injection (50 mg). Conclusion: The current study compares the cost difference between the marketed branded and Jan Aushadhi generic anticancer drugs for the first time. Replacing the costly branded anticancer drugs with Jan Aushadhi generic drugs can result in substantial cost savings. The information obtained from this cost difference analysis will be helpful for the healthcare fraternity, patients, policymakers, and society at large.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study

George¹,

Baliga²

2021

Cureus

View full text Add to dashboard Cite

show abstract

“…The percentage cost variation was calculated as per the following formula. 9,10 Percentage cost variation=…”

Section: Methodsmentioning

confidence: 99%

Cost variation analysis of statins available in India

Gopalakrishna¹,

Bose²,

Stanly³

2021

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: The current study aimed to find out the percentage cost variation among the various brands of statins marketed in India. Statins are HMG-CoA reductase inhibitors which are widely prescribed as blood cholesterol lowering agents and hence reduce illness and mortality in those who are at high risk of cardiovascular disease. There are numerous brands of statins are marketed in India.Methods: Cost of a particular drug manufactured by different companies in the same strength and the dosage form was obtained from the price list provided by the pharmaceutical companies in current index of medical specialities (CIMS) (42nd year January to April 2021). The difference in the maximum and the minimum price of the same drug manufactured by different pharmaceutical companies, cost ratio and the percentage variation in price were analysed.Results: The percentage cost variation of statins was seen highest with tablet atorvastatin 20 mg (564.06%), followed by combination of capsule atorvastatin 10 mg+aspirin 75 mg (325%) which was followed by combination of film coated tablet atorvastatin 10 mg+fenofibrate 160 mg (267.4%), tablet rosuvastatin 20 mg (171.1%), tablet lovastatin 10 mg (108.9%), combination of tablet rosuvastatin 10 mg+fenofibrate 160 mg (87.34%) and lowest was seen with tablet simvastatin 20 mg (6.0%).Conclusions: There is a very wide cost variation among different brands of statins marketed in India. The percentage cost variation was found to be the highest among the moderate intensity statins.

show abstract

“…Customers wanted 1 shop for all prescribed medications, hence a small portfolio of medications combined with persistent stock severely damaged the confidence of these establishments. (15) The extremely low sales volume of medicines as a result of stock shortages and patients' lack of awareness also e-ISSN: 2321-6794 [11] had a negative influence on operating costs. Even businesses with significant sales volumes had trouble recovering their operating costs.…”

Section: Trends Of Jan Aushadhi Pariyojana In Last 10 Yearsmentioning

confidence: 99%

Survey of the Jan Pariyojana Scheme in India and its impact on citizens during the previous decade

Kaul¹,

Gupta²

2022

Int J Drug Reg Affairs

View full text Add to dashboard Cite

It is a well-known fact that Branded medicines are sold at significantly higher prices in India. Making affordable, high-quality pharmaceuticals available on the market will help everyone, but mainly the underprivileged and destitute given the country's pervasive poverty. The Indian government has always been quite concerned about this. The Ministry of Chemicals and Fertilizers' Department of Pharmaceutical has periodically implemented a number of regulatory and financial initiatives to achieve this goal. The "Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana" is a wonderful project started by the Indian government back in 2008 for the worthy purpose of providing high quality medications at accessible prices to all. The Pariyojana involved selling inexpensive generic medications through upscale retailers called "Pradhan Mantri Bhartiya Jan Oshadhi Kendra" in different regions of the nation. On November 25, 2008, the first "Pradhan Mantri Bhartiya Jan Oshadhi Kendra" in Punjab's Amritsar city was inaugurated. At first, it was planned that the "Pradhan Mantri Bhartiya Jan Oshadhi Pariyojana" would be implemented during the 11th Five-Year Plan period, beginning in 2008-2009, with the goal of establishing at least each Pradhan Mantri Bhartiya Jan Oshadhi Kendra in each of the firm's 630 regions, and then expanding to sub divisional levels as well as major town and village centers by 2012. After garnering early support, the concept was planned to be self-sustaining and not rely on government subsidies or assistance. It was to be run on the basis of "No Profit, No Loss."

show abstract

Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India

Cited by 13 publications

References 10 publications

Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study

Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study

Cost variation analysis of statins available in India

Survey of the Jan Pariyojana Scheme in India and its impact on citizens during the previous decade

Contact Info

Product

Resources

About